Effect of sitagliptin treatment on metabolism and cardiac function in genetic diabetic mice

European Journal of Pharmacology

Volumn 723, Issue 1, 2014, Pages 175-180

  Hemmeryckx, Bianca ^a   Swinnen, Melissa ^b   Gallacher, David J ^c   Lu, Hua Rong ^c   Lijnen, H Roger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Cardiac function; Genetic Akita mice; Sitagliptin

Indexed keywords

CARDIAC FUNCTION; GENETIC AKITA MICE; SITAGLIPTIN;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEART; HEART FUNCTION TESTS; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MYOCARDIUM; PYRAZINES; TRIAZOLES;

EID: 84893784807     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.12.036     Document Type: Article

References (35)

1. B. Chen, A. Moore, L.V. Escobedo, M.S. Koletsky, D. Hou, R.J. Koletsky, and P. Ernsberger Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats Exp. Biol. Med. (Maywood) 236 2011 309 314
2. M.H. Davidson Cardiovascular effects of glucagonlike peptide-1 agonists Am. J. Cardiol. 108 2011 33B 41B
3. C.F. Deacon Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes Expert Opin. Investig. Drugs 16 2007 533 545 (Pubitemid 46554470)
4. G.P. Fadini, E. Boscaro, M. Albiero, L. Menegazzo, V. Frison, S. de Kreutzenberg, C. Agostini, A. Tiengo, and A. Avogaro The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha Diabetes Care 33 2010 1607 1609
5. L. Ferreira, E. Teixeira-de-Lemos, F. Pinto, B. Parada, C. Mega, H. Vala, R. Pinto, P. Garrido, J. Sereno, R. Fernandes, P. Santos, I. Velada, A. Melo, S. Nunes, F. Teixeira, and F. Reis Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) Mediat. Inflamm. 2010 2010 592760
6. A. Goncalves, E. Leal, A. Paiva, E. Teixeira Lemos, F. Teixeira, C.F. Ribeiro, F. Reis, A.F. Ambrosio, and R. Fernandes Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model Diabetes Obes. Metab. 14 2012 454 463
7. B. Hemmeryckx, M.F. Hoylaerts, D.J. Gallacher, Lu, H. Rong, U. Himmelreich, J. D'Hooge, M. Swinnen, and H.R. Lijnen Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice? Eur. J. Pharmacol. 700 2013 23 31
8. G.A. Herman, G.C. Mistry, B. Yi, A.J. Bergman, A.Q. Wang, W. Zeng, L. Chen, K. Snyder, J.L. Ruckle, P.J. Larson, M.J. Davies, R.B. Langdon, K.M. Gottesdiener, and J.A. Wagner Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males Br. J. Clin. Pharmacol. 71 2011 429 436
9. E.G. Hong, D.Y. Jung, H.J. Ko, Z. Zhang, Z. Ma, J.Y. Jun, J.H. Kim, A.D. Sumner, T.C. Vary, T.W. Gardner, S.K. Bronson, and J.K. Kim Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling Am. J. Physiol. Endocrinol. Metab. 293 2007 E1687 E1696
10. Y. Kubota, M. Miyamoto, G. Takagi, T. Ikeda, S. Kirinoki-Ichikawa, K. Tanaka, and K. Mizuno The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes J. Korean Med. Sci. 27 2012 1364 1370
11. M. Lenski, A. Kazakov, N. Marx, M. Bohm, and U. Laufs Effects of DPP-4 inhibition on cardiac metabolism and function in mice J. Mol. Cell Cardiol. 51 2011 906 918
12. D.H. MacIver, and M.J. Dayer An alternative approach to understanding the pathophysiological mechanisms of chronic heart failure Int. J. Cardiol. 154 2012 102 110
13. T.R. Marcy, M.L. Britton, and S.M. Blevins Second-generation thiazolidinediones and hepatotoxicity Ann. Pharmacother. 38 2004 1419 1423 (Pubitemid 39100194)
14. L. Micheli, M. Sbrilli, and C. Nencini Severe hypoglycemia associated with levofloxacin in type 2 diabetic patients receiving polytherapy: two case reports Int. J. Clin. Pharmacol. Ther. 50 2012 302 306
15. J. Mu, A. Petrov, G.J. Eiermann, J. Woods, Y.P. Zhou, Z. Li, E. Zycband, Y. Feng, L. Zhu, R.S. Roy, A.D. Howard, C. Li, N.A. Thornberry, and B.B. Zhang Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes Eur. J. Pharmacol. 623 2009 148 154
16. R.W. Nesto, D. Bell, R.O. Bonow, V. Fonseca, S.M. Grundy, E.S. Horton, M. Le Winter, D. Porte, C.F. Semenkovich, S. Smith, L.H. Young, and R. Kahn Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American heart association and american diabetes association Circulation 108 2003 2941 2948 (Pubitemid 37517824)
17. L.A. Nikolaidis, S. Mankad, G.G. Sokos, G. Miske, A. Shah, D. Elahi, and R.P. Shannon Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 2004 962 965 (Pubitemid 38282847)
18. R.M. Ortiz, C.E. Wade, D.P. Costa, and C.L. Ortiz Renal responses to plasma volume expansion and hyperosmolality in fasting seal pups Am. J. Physiol. Regul. Integr. Comp. Physiol. 282 2002 R805 R817
19. C.E. Quinn, P.K. Hamilton, C.J. Lockhart, and G.E. McVeigh Thiazolidinediones: effects on insulin resistance and the cardiovascular system Br. J. Pharmacol. 153 2008 636 645 (Pubitemid 351271751)
20. I. Raz, M. Hanefeld, L. Xu, C. Caria, D. Williams-Herman, and H. Khatami Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 49 2006 2564 2571
21. R.A. Reimer, G.J. Grover, L. Koetzner, R.J. Gahler, P. Juneja, M.R. Lyon, and S. Wood Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats J. Nutr. 142 2012 1812 1820
22. M. Reynolds Plasma and blood volume in the cow using the T-1824 hematocrit method Am. J. Physiol. 173 1953 421 427
23. R. Scott, M. Wu, M. Sanchez, and P. Stein Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int. J. Clin. Pract. 61 2007 171 180
24. N. Selvaraj, Z. Bobby, and M.G. Sridhar Increased glycation of hemoglobin in chronic renal failure: [corrected] potential role of oxidative stress Arch. Med. Res. 39 2008 277 284 (Pubitemid 351221153)
25. E. Selvin, J. Coresh, J. Jordahl, L. Boland, and M.W. Steffes Stability of hemoglobin A1c (HbA1c) measurements from frozen whole blood samples stored for over a decade Diabet. Med. 22 2005 1726 1730 (Pubitemid 43046475)
26. J.E. Shaw, R.A. Sicree, and P.Z. Zimmet Global estimates of the prevalence of diabetes for 2010 and 2030 Diabetes Res. Clin. Pract. 87 2010 4 14
27. S.A. Stein, E.M. Lamos, and S.N. Davis A review of the efficacy and safety of oral antidiabetic drugs Expert Opin. Drug Saf. 12 2013 153 175
28. D. Stejskal, V. Ruzicka, S. Adamovska, R. Jurakova, J. Proskova, L. Jedelsky, and J. Bartek Adiponectin concentrations as a criterion of metabolic control in persons with type 2 diabetes mellitus? Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub. 147 2003 167 172
29. J. Stypmann, M.A. Engelen, C. Troatz, M. Rothenburger, L. Eckardt, and K. Tiemann Echocardiographic assessment of global left ventricular function in mice Lab. Anim. 43 2009 127 137
30. E. Takimoto, and D.A. Kass Role of oxidative stress in cardiac hypertrophy and remodeling Hypertension 49 2007 241 248 (Pubitemid 46142995)
31. S.I. Taylor Deconstructing type 2 diabetes Cell 97 1999 9 12 (Pubitemid 29165884)
32. F. Vittone, A. Liberman, D. Vasic, R. Ostertag, M. Esser, D. Walcher, A. Ludwig, N. Marx, and M. Burgmaier Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice Diabetologia 55 2012 2267 2275
33. X.Q. Yang, and A.F. Chen High-cholesterol diet augments endothelial dysfunction via elevated oxidative stress and reduced tetrahydrobiopterin in Ins2(Akita) mice, an autosomal dominant mutant type 1 diabetic model Clin. Exp. Pharmacol. Physiol. 36 2009 764 769
34. M. Yoshioka, T. Kayo, T. Ikeda, and A. Koizumi A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice Diabetes 46 1997 887 894 (Pubitemid 27188269)
35. P. Zimmet, K.G. Alberti, and J. Shaw Global and societal implications of the diabetes epidemic Nature 414 2001 782 787 (Pubitemid 34000780)